The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

Summary

There is no confirmed drug therapy for RP-ILD. Prognosis is poor of regular treatment. The study is designed to compare efficacy and safety of tocilizumab versus regular treatment in participants with severe RP-ILD secondary to systemic diseases.

Timeline

Start

2021-02-22

Primary completion

2022-09-01

Completion

2022-09-01

Drugs

Indications